Reduction of menstrual blood-loss by prostaglandin-synthetase inhibitors.
ABSTRACT Six patients with menorrhagia due to dysfunctional uterine bleeding and one patient with an intrauterine contraceptive device were treated with prostaglandin-synthetase inhibitors in an attempt to reduce their excessive menstrual blood-loss. Mefenamic acid (six patients) or flufenamic acid (one patient) taken during menstruation for 2-3 cycles reduced menstrual loss in each patient. These preliminary observations suggest a new treatment for a common gynaecological problem and could imply that prostaglandins are involved in the aetiology of excessive menstrual blood-loss in such patients.
- SourceAvailable from: Fady Moiety[Show abstract] [Hide abstract]
ABSTRACT: IntroductionExcessive menstrual loss is a major problem. Effective medical treatments exist and may provide an alternative to surgery.Middle East Fertility Society Journal 01/2010; 15(3):163-167.
- [Show abstract] [Hide abstract]
ABSTRACT: . A randomized trial was arranged in Yorkshire to assess whether progestogens would improve survival as part of the primary treatment of endometrial carcinoma, in conjunction with surgery and radiotherapy. A total of 429 patients was randomized on diagnosis to the progestogen or control group and treated locally according to an agreed protocol. All the patients are now more than 1 year after operation and over half are more than 5 years after operation. The projected overall 5-year survival rate is 76% but contrary to expectation there is no statistically significant difference in survival between the patients treated with progestogens and the control group even after statistical adjustment for known prognostic factors.BJOG An International Journal of Obstetrics & Gynaecology 02/1988; 95(2). · 3.76 Impact Factor